Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Xeljanz, Rinvoq, and Olumiant Safety Review by European Drug Regulator EMA

February 16, 2022 By Law Offices of Thomas J. Lamb, P.A.

The JAK inhibitors drug class safety issue has landed in Europe, as indicated by this European Medicines Agency (EMA) February 11, 2022, news item, “EMA starts safety review of Janus kinase inhibitors for inflammatory disorders”. This Xeljanz, Rinvoq, and Olumiant safety review by the EMA follows a December 2021 JAK inhibitors drug class safety FDA … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancers, cardiovascular deaths, cardiovascular events, Heart Attacks, Olumiant, Rinvoq, Strokes, Xeljanz

Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021

September 7, 2021 By Law Offices of Thomas J. Lamb, P.A.

On September 1, 2021, we saw new FDA Xeljanz warnings about the increased risks of heart attacks, strokes, cancer, blood clots, and deaths. These Xeljanz drug safety problems have been associated with all doses of Xeljanz (5 mg tablet and 10 mg tablet) and Xeljanz XR (11 mg tablet and 22 mg tablet). This September 2021 document, “FDA requires … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancer, Heart Attacks, heart problems, Strokes, Xeljanz

Tasigna Drug Injury Lawsuits Federal Court MDL Consolidation Order

August 24, 2021 By Law Offices of Thomas J. Lamb, P.A.

There is a newly created Tasigna multi-district litigation (MDL) for those Tasigna drug injury lawsuits filed in the federal court system.  We get some of the reasoning for this consolidation of Tasigna side effects cases from the August 10, 2021, JPML Transfer Order issued for IN RE: TASIGNA (NILOTINIB) PRODUCTS LIABILITY LITIGATION, MDL No. … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Aneurysms, Brain Aneurysm, Cerebrovascular Accidents (CVA), chronic kidney disease, Deep Vein Thrombosis (DVT), Heart Attacks, ischemic cerebrovascular disease, ischemic heart disease, Kidney Failure, Myocardial Infarctions (MI), peripheral arterial disease (PAD), peripheral arterial occlusive disease (PAOD), Pulmonary Embolism (PE), Renal Failure, Strokes, Tasigna

FDA Advisory Committee Meeting Could Review Risk/Benefit Profiles for All JAK Inhibitors

July 8, 2021 By Law Offices of Thomas J. Lamb, P.A.

The FDA has delayed its decision for Abbvie’s applications to have Rinvoq approved for the additional indications of psoriatic arthritis and ankylosing spondylitis, apparently due to possible new JAK inhibitors heart side effects and cancer risks issues identified in connection with a Xeljanz safety signal. From this June 25, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancer, Heart Attacks, Rinvoq, Strokes, Xeljanz

Tasigna Lawsuits Update: New Jersey MCL and Federal Court MDL Consolidations

June 21, 2021 By Law Offices of Thomas J. Lamb, P.A.

We are currently investigating Tasigna side effects cases as possible Tasigna drug injury lawsuits against Novartis for patients who have developed some serious medical conditions during their use of Tasigna. In early June 2021, the New Jersey Supreme Court consolidated Tasigna drug injury lawsuits filed against Novartis Pharmaceuticals Corp. … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Heart Attacks, lower limb amputations, Strokes, Tasigna

Lemtrada Safety Issues Lead To Use Restrictions In Europe

November 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

Drug safety regulators for the European Union recently recommended that Lemtrada use be restricted to certain limited patient populations due to serious side effects linked to Lemtrada. This November 5, 2019 Multiple Sclerosis News Today report, “EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding disorders, bleeding in the lungs, Heart Attacks, Hepatitis, Lemtrada, liver damage, Strokes

Imbruvica Increases Risks Of Myocardial Infarctions, Strokes, And Cardiovascular Deaths

October 24, 2019 By Law Offices of Thomas J. Lamb, P.A.

Serious heart-related side effects such as myocardial infarctions, strokes, and cardiovascular deaths associated with Imbruvica (ibrutinib), according to this medical journal article, “Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation”, published in early October 2019. From the Abstract for this Blood medical journal … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cardiovascular deaths, Imbruvica, Myocardial Infarctions (MI), Strokes

Uloric Warning: Avoid Uloric If Prior Myocardial Infarction, Stroke, Or Unstable Angina

August 5, 2019 By Law Offices of Thomas J. Lamb, P.A.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a Uloric warning in July 2019 stating that patients with prior myocardial infarction, stroke, or unstable angina should avoid Uloric as there is a higher risk of death. From this July 2019 MHRA Drug Safety Update, “Febuxostat (Adenuric): increased risk of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Myocardial Infarctions (MI), Strokes, Uloric

Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects

July 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this summary: While an urgent [European Union (EU)] safety … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Autoimmune Hepatitis, Heart Attacks, Lemtrada, Strokes

Uloric Lawsuits Follow Recent FDA Warnings About Heart-Related Deaths And Side Effects

May 1, 2019 By Law Offices of Thomas J. Lamb, P.A.

Following recent FDA-mandated label changes, there have been Uloric lawsuits filed against Takeda Pharmaceuticals America, Inc., the manufacturer of Uloric. Uloric (febuxostat) tablets have been generally prescribed for the management of chronic gout since 2009. In February 2019 the FDA required its strongest safety warning, i.e., Bolded … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Heart Attacks, Strokes, Uloric

  • 1
  • 2
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.